Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback